<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535663</url>
  </required_header>
  <id_info>
    <org_study_id>YF_immune</org_study_id>
    <nct_id>NCT02535663</nct_id>
  </id_info>
  <brief_title>Consumption of Dairy Yogurt Enhanced Immune Function</brief_title>
  <official_title>Consumption of Dairy Yogurt With Rhamnogalacturonan in Korean Citrus Hallabong Peel Polysaccharide Enhanced Immune Function and Attenuated Inflammatory Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the impact of consumption of dairy yogurt with rhamnogalacturonan (RG) in
      Korean citrus Hallabong peel polysaccharide on Natural Killer (NK) cell activity and
      circulating cytokine levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled study was conducted on 120 nondiabetic and
      nonobese subjects. Over an 8 week period, the test group consumed one pack (150ml) of dairy
      yogurt with 50mg probiotics and 100mg Korean citrus Hallabong peel polysaccharide (60% RG,
      20% mono- and di-saccharide, 5% polyphenol) each day, whereas the placebo group consumed the
      same product without Korean citrus Hallabong peel polysaccharide. NK cell activities (%) were
      measured based on the ratios of effector cells (E) (peripheral blood mononuclear cell, PBMC)
      from each participant to Target cell (T) (K562 cells) as 10:1, 5:1, 2.5:1 or 1.25:1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum cytokine concentrations</measure>
    <time_frame>change from baseline in RG at 8 weeks</time_frame>
    <description>Primary outcome will be tested before and after intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: RG consumed one pack (150ml) of dairy yogurt containing RG (100mg Korean citrus Hallabong peel polysaccharide) per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: placebo consumed one pack (150ml) of dairy yogurt without RG per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>RG</intervention_name>
    <description>The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture</description>
    <arm_group_label>test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same product without RG</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The levels of white blood cells under 8x10^3/Î¼L

          -  males and females

          -  30-69 years old

          -  nondiabetic and nonobese subjects

          -  able to give informed consent

        Exclusion Criteria:

          -  consumption of any probiotic products within 1 month before screening

          -  unstable body weight (body-weight change &gt; 2 kg within 3 months before screening)

          -  diabetes

          -  history/presence of significant metabolic disease

          -  pregnancy or breast-feeding

          -  acute or chronic infection

          -  liver disease, kidney disease, gastrointestinal disease, or any other acute or chronic
             disease requiring treatment

          -  subjects taking any drugs or supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong-Ho Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>120-749</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rhamnogalacturonan</keyword>
  <keyword>Natural killer cell activity</keyword>
  <keyword>interleukin-12</keyword>
  <keyword>interferon-gamma</keyword>
  <keyword>immune function</keyword>
  <keyword>inflammatory</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

